Royalty Pharma Plc (RPRX) — Strategic Asset Allocation Index
Royalty Pharma Plc (RPRX) has a Strategic Asset Allocation Index of 175.0% as of March 2026. Strategic assets (PP&E of $- plus long-term investments of $17.39 Billion) total $17.39 Billion, measured against net assets of $9.94 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check RPRX financial resilience to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Royalty Pharma Plc Strategic Asset Allocation Index (2000–2025)
This chart shows how Royalty Pharma Plc's Strategic Asset Allocation Index has evolved across 24 annual periods from 2000 to 2025. As of March 2026, the index stands at 175.0%, representing strategic assets of $17.39 Billion against net assets of $9.94 Billion USD. See Royalty Pharma Plc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Royalty Pharma Plc (2000–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Royalty Pharma Plc from 2000 to 2025, covering 24 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Royalty Pharma Plc (RPRX) total market value.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 175.9% | $17.09 Billion | $- | $17.09 Billion | $9.71 Billion | ▲ +17.5 pp |
| 2024 | 158.4% | $16.39 Billion | $- | $16.39 Billion | $10.34 Billion | ▲ +8.7 pp |
| 2023 | 149.7% | $15.10 Billion | $- | $15.10 Billion | $10.08 Billion | ▲ +1.5 pp |
| 2022 | 148.2% | $14.12 Billion | $- | $14.12 Billion | $9.53 Billion | ▲ +8.1 pp |
| 2021 | 140.1% | $14.36 Billion | $- | $14.36 Billion | $10.25 Billion | ▲ +53.5 pp |
| 2020 | 86.6% | $12.97 Billion | $- | $12.97 Billion | $14.97 Billion | ▼ -100.3 pp |
| 2019 | 186.9% | $11.48 Billion | $- | $11.48 Billion | $6.14 Billion | ▼ -3.5 pp |
| 2018 | 190.4% | $8.67 Billion | $- | $8.67 Billion | $4.55 Billion | ▲ +190.4 pp |
| 2016 | 0.0% | $3.00K | $3.00K | $- | $4.46 Billion | ▼ 0.0 pp |
| 2015 | 0.0% | $8.00K | $8.00K | $- | $4.70 Billion | ▼ -0.1 pp |
| 2014 | 0.1% | $32.00K | $32.00K | $- | $44.02 Million | ▼ 0.0 pp |
| 2013 | 0.1% | $75.00K | $75.00K | $- | $75.42 Million | ▼ -0.1 pp |
| 2012 | 0.2% | $53.00K | $53.00K | $- | $23.03 Million | ▼ -0.1 pp |
| 2011 | 0.3% | $15.00K | $15.00K | $- | $4.67 Million | ▲ +0.1 pp |
| 2010 | 0.2% | $7.00K | $7.00K | $- | $3.17 Million | ▼ -1.9 pp |
| 2009 | 2.1% | $12.00K | $12.00K | $- | $562.00K | ▲ +2.0 pp |
| 2008 | 0.2% | $28.00K | $28.00K | $- | $15.61 Million | ▼ 0.0 pp |
| 2007 | 0.2% | $47.00K | $47.00K | $- | $24.06 Million | ▼ -1.5 pp |
| 2006 | 1.7% | $65.00K | $65.00K | $- | $3.79 Million | ▲ +1.6 pp |
| 2005 | 0.1% | $19.00K | $19.00K | $- | $16.95 Million | ▼ -0.2 pp |
| 2004 | 0.3% | $18.00K | $18.00K | $- | $5.99 Million | ▼ -0.4 pp |
| 2002 | 0.7% | $191.00K | $191.00K | $- | $26.85 Million | ▼ -0.4 pp |
| 2001 | 1.1% | $340.00K | $340.00K | $- | $30.57 Million | ▼ -0.7 pp |
| 2000 | 1.8% | $556.00K | $556.00K | $- | $31.06 Million | — |